DIA Biosimilars 2013

Awards & Advancement

Creabilis appoints Simon Russell as chief business officer

Friday, May 4, 2012 04:43 PM

Creabilis, a European biotech specializing in the development of treatments for dermatology, inflammation and pain, has appointed Simon Russell as chief business officer.

More... »

Cenduit: Now with Patient Reminders

GSK adds two non-executive directors to its board

Friday, May 4, 2012 08:00 AM

GlaxoSmithKline (GSK) has appointed Lynn Elsenhans and Jing Ulrich as non-executive directors to the company’s board, beginning July 1, 2012.

More... »

CRF Health – eCOA Forum

Covance announces executive appointments

Friday, May 4, 2012 04:08 AM

Covance, a Princeton, N.J.-based provider of drug development services, has promoted Bill Klitgaard to corporate senior vice president and chief information officer, and Alison Cornell to corporate vice president and chief financial officer, effective May 8 upon approval by the board of directors.

More... »

Regulus Therapeutics appoints Bruce Carter to board of directors

Wednesday, May 2, 2012 04:38 PM

Regulus Therapeutics, a biopharmaceutical company focused on medicines targeting microRNAs, has appointed Bruce Carter, Ph.D., to its board of directors.

More... »

NIH awards ImmuVen $1.68 million grant

Wednesday, May 2, 2012 11:54 AM

ImmuVen, a biotech based in Champaign, Ill., was awarded a phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease.

More... »

Benchmark Research wins ViE Award for best clinical trial site

Tuesday, May 1, 2012 11:03 AM

Benchmark Research’s Austin, Texas location was recognized as Best Clinical Trial Site at the 2012 Vaccine Industry Excellence (ViE) Awards, held during the Annual World Vaccine Congress.

More... »

Recipients of 2012 SAFE-Biopharma Digi Award named

Monday, April 30, 2012 04:52 PM

Recipients have been selected for the 2012 SAFE-BioPharma Digi Award, recognizing innovative uses of the global SAFE-BioPharma digital identity and digital signature standard and the institutions and individuals contributing to broader understanding of its benefits. Recipients included: Astellas, Bristol-Myers Squibb and representatives of two U.S. government entities.

More... »

AMRI hires director of in vitro biology in Singapore

Monday, April 30, 2012 04:41 PM

AMRI, a global CRO, has added Saravanakumar Dhakshinamoorthy, Ph.D., to the ranks of its management team in Singapore, serving as director of in vitro biology.

More... »

Almac rewarded for excellence in technology

Monday, April 30, 2012 04:33 PM

Service provider Almac has been recognized for its technological developments, scooping a top award at the recent Belfast Telegraph Northern Ireland Business Awards 2012, in association with British Midland International (BMI).

More... »

Quintiles names Tom Pike CEO

Monday, April 23, 2012 10:01 AM

Quintiles, a global biopharmaceutical services company, has appointed Tom Pike as CEO effective April 30 as part of the company’s long-term succession planning. 

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs